Saul A. Schepartz
About
In The Last Decade
Saul A. Schepartz
34 papers receiving 1.6k citations
Hit Papers
Peers
Comparison fields: 5 of 98
- Molecular Biology 740
- Oncology 494
- Organic Chemistry 487
- Pharmacology 232
- Cancer Research 214
Countries citing papers authored by Saul A. Schepartz
This map shows the geographic impact of Saul A. Schepartz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saul A. Schepartz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saul A. Schepartz more than expected).
Fields of papers citing papers by Saul A. Schepartz
This network shows the impact of papers produced by Saul A. Schepartz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saul A. Schepartz. The network helps show where Saul A. Schepartz may publish in the future.
Co-authorship network of co-authors of Saul A. Schepartz
This figure shows the co-authorship network connecting the top 25 collaborators of Saul A. Schepartz. A scholar is included among the top collaborators of Saul A. Schepartz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Saul A. Schepartz. Saul A. Schepartz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials breakdown → | 621 |
| 2 | 17 | |
| 3 | 210 | |
| 4 | 27 | |
| 5 | 2 | |
| 6 | Antitumor screening procedures of the National Cancer Institute. | 5 |
| 7 | Icrf-159 (1,2-bis(3,5-dioxopiperazin-1-yl)propane) (nsc-129943). Activity against intracerebrally inoculated l1210, therapeutic superiority against ip l1210 in combination with cis-platinum (ii) diamminodichloride (cis-pt-ii. Nsc-119875). Abstr. | 2 |
| 8 | Screening data from the Cancer Chemotherapy National Service Center screening laboratories. XL. Plant extracts. | 15 |
| 9 | Screening data from the Cancer Chemotherapy National Service Center Screening Laboratories. XLI. Plant extracts. | 4 |
| 10 | Screening Data from the Cancer Chemotherapy National Service Center Screening Laboratories, XXXVII. Plant Extracts | 1 |
| 11 | Screening data from the Cancer Chemotherapy National Service Center screening laboratories. 33. Plant extracts. | 4 |
| 12 | SCREENING DATA FROM THE CANCER CHEMOTHERAPY NATIONAL SERVICE CENTER SCREENING LABORATORIES. XXII. | 4 |
| 13 | Screening data from the Cancer Chemotherapy National Service Center Screening Laboratories. 28. | 19 |
| 14 | SCREENING DATA FROM THE CANCER CHEMOTHERAPY NATIONAL SERVICE CENTER SCREENING LABORATORIES. XXVII. | 2 |
| 15 | SCREENING DATA FROM THE CANCER CHEMOTHERAPY NATIONAL SERVICE CENTER SCREENING LABORATORIES. XIV. | 1 |
| 16 | Screening data from the Cancer Chemotherapy National Service Center Screening Laboratories. IX. Plant extracts. | 3 |
| 17 | Screening data from the Cancer Chemotherapy National Service Center screening laboratories. X. Cell culture cytotoxicity tests. | 1 |
| 18 | Freezing and preservation of mouse tumor slices. | 3 |
| 19 | 14 | |
| 20 | 7 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.